The growth in the historic period can be attributed to advancement in stem cell transplantation, expansion of cord blood banking, improved transplant survival rates, oncology treatment evolution, regulatory approvals.
The growth in the forecast period can be attributed to increased use in genetic disorders, regenerative medicine investments, expansion of transplant infrastructure, improved matching technologies, global stem cell banking growth. Major trends in the forecast period include growth in cord blood stem cell transplantation, expansion of allogeneic cell therapies, rising demand for regenerative treatments, improved cryopreservation technologies, specialized transplant center development.
The growing prevalence of chronic diseases is expected to drive the expansion of the Cordcyte market in the coming years. Chronic diseases are long-lasting conditions that require ongoing management and treatment. Their increasing prevalence is influenced by factors such as an aging population, unhealthy lifestyle choices, and environmental factors. Cordcyte is used in clinical settings for regenerative therapy, utilizing stem cells derived from umbilical cord blood to treat conditions including hematological disorders, immune deficiencies, and neurodegenerative diseases. For example, in September 2025, the British Heart Foundation, a UK-based charity, reported that over 7.6 million people in the UK - more than 4 million men and over 3.6 million women - are living with cardiovascular disease. Projections indicate that, driven by an aging population and improved survival rates, the number of affected individuals could rise by around 1 million by 2030 and approximately 2 million by 2040. As a result, the increasing prevalence of chronic diseases is fueling the growth of the Cordcyte market.
The rising healthcare expenditure is expected to support the growth of the Cordcyte market. Healthcare expenditure refers to the total spending on health services and products over a given period. Factors such as an aging population, increasing healthcare costs, and technological advancements in medicine contribute to this growth. Higher healthcare expenditure facilitates the development of Cordcyte applications by funding research, clinical trials, and infrastructure, enabling broader access to regenerative therapies for complex diseases. For instance, in April 2025, the Office for National Statistics (ONS), a UK-based independent producer of official statistics, reported that total healthcare expenditure increased by 6.5% in nominal terms and 2.4% in real terms between 2023 and 2024, while healthcare’s share of GDP remained steady at 11.1% in 2024, the same as the previous year. Therefore, the rising healthcare expenditure is driving the expansion of the Cordcyte market.
The increasing number of clinical trials is expected to accelerate the growth of the Cordcyte market. The rise in clinical trials is driven by growing demand for innovative treatments, advancements in stem cell technologies, and regulatory support for new therapeutic applications. Clinical trials demonstrate the safety and efficacy of Cordcyte, paving the way for regulatory approvals and wider adoption in treatment protocols. For example, the American Society of Gene & Cell Therapy, a US-based non-profit medical and scientific organization, reported that the number of gene therapies in Phase III clinical trials grew by 10% in Q3 2023, marking the first quarterly increase since Q3 2022. Consequently, the rising number of clinical trials is boosting the growth of the Cordcyte market.
Major companies operating in the cordcyte market are LifeSouth Community Blood Centers Inc.
North America was the largest region in the cordcyte market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cordcyte market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cordcyte market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have influenced the cordcyte market by increasing costs related to cryogenic storage equipment, biologic transport containers, and cell processing materials. These impacts are most visible in transplant centers across north america and europe. Import duties have affected international stem cell distribution. Regulatory compliance requirements have also extended delivery timelines. However, tariffs are supporting regional stem cell banking and strengthening localized cell therapy ecosystems.
The cordcyte market research report is one of a series of new reports that provides cordcyte market statistics, including cordcyte industry global market size, regional shares, competitors with a cordcyte market share, detailed cordcyte market segments, market trends and opportunities, and any further data you may need to thrive in the cordcyte industry. This cordcyte market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cordcyte is a therapeutic product derived from human cord blood, specifically containing hematopoietic progenitor cells. It is used in allogeneic hematopoietic stem cell transplants, mainly for patients with hematopoietic system disorders, including inherited conditions or those caused by treatments like chemotherapy. These cells are infused into patients to aid in the regeneration of blood and immune systems.
Cordcyte is available in formulations such as cord blood stem cells and cryopreserved units. Cord blood stem cells are potent cells from umbilical cord blood capable of developing into various cell types. They are used to treat medical conditions like cancers, blood disorders, and immune deficiencies and are preferred due to their lower risk of transplant rejection. The product is indicated for hematological, genetic, and immune system disorders and is distributed through hospital pharmacies, stem cell banks, and outpatient clinics.
The cordcyte market consists of sales of exosome-based products, stem cell transplants, and cell storage devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The growth in the forecast period can be attributed to increased use in genetic disorders, regenerative medicine investments, expansion of transplant infrastructure, improved matching technologies, global stem cell banking growth. Major trends in the forecast period include growth in cord blood stem cell transplantation, expansion of allogeneic cell therapies, rising demand for regenerative treatments, improved cryopreservation technologies, specialized transplant center development.
The growing prevalence of chronic diseases is expected to drive the expansion of the Cordcyte market in the coming years. Chronic diseases are long-lasting conditions that require ongoing management and treatment. Their increasing prevalence is influenced by factors such as an aging population, unhealthy lifestyle choices, and environmental factors. Cordcyte is used in clinical settings for regenerative therapy, utilizing stem cells derived from umbilical cord blood to treat conditions including hematological disorders, immune deficiencies, and neurodegenerative diseases. For example, in September 2025, the British Heart Foundation, a UK-based charity, reported that over 7.6 million people in the UK - more than 4 million men and over 3.6 million women - are living with cardiovascular disease. Projections indicate that, driven by an aging population and improved survival rates, the number of affected individuals could rise by around 1 million by 2030 and approximately 2 million by 2040. As a result, the increasing prevalence of chronic diseases is fueling the growth of the Cordcyte market.
The rising healthcare expenditure is expected to support the growth of the Cordcyte market. Healthcare expenditure refers to the total spending on health services and products over a given period. Factors such as an aging population, increasing healthcare costs, and technological advancements in medicine contribute to this growth. Higher healthcare expenditure facilitates the development of Cordcyte applications by funding research, clinical trials, and infrastructure, enabling broader access to regenerative therapies for complex diseases. For instance, in April 2025, the Office for National Statistics (ONS), a UK-based independent producer of official statistics, reported that total healthcare expenditure increased by 6.5% in nominal terms and 2.4% in real terms between 2023 and 2024, while healthcare’s share of GDP remained steady at 11.1% in 2024, the same as the previous year. Therefore, the rising healthcare expenditure is driving the expansion of the Cordcyte market.
The increasing number of clinical trials is expected to accelerate the growth of the Cordcyte market. The rise in clinical trials is driven by growing demand for innovative treatments, advancements in stem cell technologies, and regulatory support for new therapeutic applications. Clinical trials demonstrate the safety and efficacy of Cordcyte, paving the way for regulatory approvals and wider adoption in treatment protocols. For example, the American Society of Gene & Cell Therapy, a US-based non-profit medical and scientific organization, reported that the number of gene therapies in Phase III clinical trials grew by 10% in Q3 2023, marking the first quarterly increase since Q3 2022. Consequently, the rising number of clinical trials is boosting the growth of the Cordcyte market.
Major companies operating in the cordcyte market are LifeSouth Community Blood Centers Inc.
North America was the largest region in the cordcyte market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cordcyte market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cordcyte market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have influenced the cordcyte market by increasing costs related to cryogenic storage equipment, biologic transport containers, and cell processing materials. These impacts are most visible in transplant centers across north america and europe. Import duties have affected international stem cell distribution. Regulatory compliance requirements have also extended delivery timelines. However, tariffs are supporting regional stem cell banking and strengthening localized cell therapy ecosystems.
The cordcyte market research report is one of a series of new reports that provides cordcyte market statistics, including cordcyte industry global market size, regional shares, competitors with a cordcyte market share, detailed cordcyte market segments, market trends and opportunities, and any further data you may need to thrive in the cordcyte industry. This cordcyte market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cordcyte is a therapeutic product derived from human cord blood, specifically containing hematopoietic progenitor cells. It is used in allogeneic hematopoietic stem cell transplants, mainly for patients with hematopoietic system disorders, including inherited conditions or those caused by treatments like chemotherapy. These cells are infused into patients to aid in the regeneration of blood and immune systems.
Cordcyte is available in formulations such as cord blood stem cells and cryopreserved units. Cord blood stem cells are potent cells from umbilical cord blood capable of developing into various cell types. They are used to treat medical conditions like cancers, blood disorders, and immune deficiencies and are preferred due to their lower risk of transplant rejection. The product is indicated for hematological, genetic, and immune system disorders and is distributed through hospital pharmacies, stem cell banks, and outpatient clinics.
The cordcyte market consists of sales of exosome-based products, stem cell transplants, and cell storage devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Cordcyte Market Characteristics
3. Cordcyte Market Supply Chain Analysis
4. Global Cordcyte Market Trends and Strategies
5. Cordcyte Market Analysis of End Use Industries
7. Global Cordcyte Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Cordcyte Total Addressable Market (TAM) Analysis for the Market
9. Cordcyte Market Segmentation
10. Cordcyte Market Regional and Country Analysis
11. Asia-Pacific Cordcyte Market
12. China Cordcyte Market
13. India Cordcyte Market
14. Japan Cordcyte Market
15. Australia Cordcyte Market
16. South Korea Cordcyte Market
17. Western Europe Cordcyte Market
18. UK Cordcyte Market
19. Germany Cordcyte Market
20. France Cordcyte Market
21. Eastern Europe Cordcyte Market
22. North America Cordcyte Market
23. USA Cordcyte Market
24. Canada Cordcyte Market
25. South America Cordcyte Market
26. Middle East Cordcyte Market
27. Africa Cordcyte Market
29. Cordcyte Market Competitive Landscape and Company Profiles
32. Cordcyte Market High Potential Countries, Segments and Strategies
33. Appendix
Executive Summary
Cordcyte Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses cordcyte market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cordcyte? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cordcyte market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Formulation: Cord Blood Stem Cells; Cryopreserved Units2) By Indication: Hematological Disorders; Genetic Disorders; Immune System Disorders
3) By Distribution Channel: Hospital Pharmacies; Stem Cell Banks; Outpatient Clinics
Companies Mentioned: LifeSouth Community Blood Centers Inc.
Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Cordcyte market report include:- LifeSouth Community Blood Centers Inc.
